The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Open accessAbstract
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages the nigrostriatal dopaminergic pathway as seen in Parkinson's disease (PD), a common neurodegenerative disorder with no effective protective treatment. Consistent with a role of glial cells in PD neurodegeneration, here we show that minocycline, an approved tetracycline derivative that inhibits microglial activation independently of its antimicrobial properties, mitigates both the demise of nigrostriatal dopaminergic neurons and the formation of nitrotyrosine produced by MPTP. In addition, we show that minocycline not only prevents MPTP-induced activation of microglia but also the formation of mature interleukin-1beta and the activation of NADPH-oxidase and inducible nitric oxide synthase (iNOS), three key microglial-derived cytotoxic mediators. Previously, we demonstrated that ablation of iNOS attenuates MPTP-induced neurotoxicity. Now, we demonstrate that iNOS is not the only microglial-related culprit implicated in MPTP-induced toxicity because mutant iNOS-deficient mice treated with minocycline are more resistant to this neurotoxin than iNOS-deficient mice not treated with minocycline. This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect is mainly ascribable to the minocycline-dependent suppression of microglia activation, which has been reported by several in vivo studies [251,258,259,260,261,262,263].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals in biology and medicine
Gutteridge, J. M. C. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Free Radicals in Biology and Medicine
Land, E. J. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,871
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 19×
“…decreases MPTP-mediated nitrotyrosine formation A significant part of the MPTP neurotoxic process is mediated by NO-related oxidative damage (Przedborski et al., 2000), the extent of which can be evaluated by assessing nitrotyrosine levels (Liberatore et al., 1999; Pennathur et al., 1999).”
BackgroundMethodResultInfluentialYrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,032
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Research works printed but not linked: 1
- Fahn S, Przedborski S (2000) Parkinsonism. In: Merritt's neurology (Rowland LP, ed), pp 679 -693. New York: Lippincott Williams & Wilkins.
Cited by
Sorted by citations
Items 501–600 of 999
Lin, S., Wei, X., Bales, K. R., Paul, A. B. C., Ma, Z., Yan, G., Paul, S. M., & Du, Y. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04182.x · Cited by 69
Bézard, E., Gerlach, I., Moratalla, R., Gross, C. E., & Jork, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.003 · Cited by 69
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Cronin, A., & Grealy, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.018 · Cited by 68
Desplats, P., Gutierrez, A. M., Antonelli, M. C., & Frasch, M. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.013 · Cited by 74
Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome
Siller, S. S., & Broadie, K. S. (2012) · Neural Plasticity · doi:10.1155/2012/124548 · Cited by 70
Martin, H. L., Mounsey, R. B., Mustafa, S., Sathe, K., & Teismann, P. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.02.017 · Cited by 71
The Role of Glia in Alpha-Synucleinopathies
Fellner, L., & Stefanova, N. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8340-3 · Cited by 69
Martín, A., Boisgard, R., Kassiou, M., Dollé, F., & Tavitian, B. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0324-y · Cited by 68
Ma, L., Nagai, J., & Ueda, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06955.x · Cited by 67
Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study
Syngle, A., Verma, I., Krishan, P., Garg, N. B., & Syngle, V. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1647-2 · Cited by 67
Noble, W. J., Garwood, C. J., & Hanger, D. P. (2009) · Prion · doi:10.4161/pri.3.2.8820 · Cited by 67
Vroon, A., Drukarch, B., Bol, J. G. J. M., Cras, P. P., Brevé, J. J. P., Allan, S. M., Relton, J. K., Hoogland, P. V. J. M., & van Dam, A. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.04.010 · Cited by 66
Hydrogen-rich saline reduces delayed neurologic sequelae in experimental carbon monoxide toxicity
Sun, Q., Cai, J., Zhou, J., Tao, H., Zhang, J. H., Zhang, W., & Sun, X. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206bf44 · Cited by 67
Chen, J., Wersinger, C., & Sidhu, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303094200 · Cited by 67
Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice
Cardenas, H., & Bolin, L. M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03172-x · Cited by 67
Fernagut, P., Diguet, E., Bioulac, B. H., & Tison, F. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.09.014 · Cited by 67
Disease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 67
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Berg, J., Roch, M., Altschüler, J., Winter, C., Schwerk, A. M. K., Kurtz, A., & Steiner, B. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9551-y · Cited by 66
Febbraro, F., Andersen, K. J., Sánchez-Guajardo, V., Tentillier, N., & Romero‐Ramos, M. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.017 · Cited by 66
Hou, L., Zhou, X., Zhang, C., Wang, K., Liu, X., Che, Y., Sun, F., Li, H., Wang, Q., Zhang, D., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.016 · Cited by 68
Chou, M., Wu, J.-W., Gouel, F., Jonneaux, A., Timmerman, K., Renn, T., Laloux, C., Chang, H., Lin, L., Devedjian, J.-C., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.018 · Cited by 66
Schutt, C. R., Gendelman, H. E., & Mosley, R. L. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0255-7 · Cited by 64
Gong, J., Szegő, É. M., Leonov, A., Benito, E., Becker, S., Fischer, A., Zweckstetter, M., Outeiro, T. F., & Schneider, A. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2070-18.2019 · Cited by 70
Ryu, J. K., & McLarnon, J. G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.016 · Cited by 66
Basurco, L., Abellanas, M. A., Ayerra, L., Conde, E., Vinueza‐Gavilanes, R., Luquin, E., Vales, Á., Vilas, A., Martín‐Úriz, P. S., Tamayo, I., et al. (2022) · Glia · doi:10.1002/glia.24295 · Cited by 66
Hashimoto, K., Tsukada, H., Nishiyama, S., Fukumoto, D., Kakiuchi, T., & Iyo, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.019 · Cited by 65
Hurley, S. D., O'Banion, M., Song, D. D., Arana, F. S., Olschowka, J., & Haber, S. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00273-5 · Cited by 69
Bel, E. A. D., Bortolanza, M., Pereira, M. D. S., Bariotto‐dos‐Santos, K., & Raisman‐Vozari, R. (2016) · Synapse · doi:10.1002/syn.21941 · Cited by 67
Astroglial and microglial contributions to iron metabolism disturbance in Parkinson's disease
Song, N., Wang, J., Jiang, H. F., & Xie, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.008 · Cited by 63
Kanaan, N. M., Kordower, J. H., & Collier, T. J. (2008) · Glia · doi:10.1002/glia.20690 · Cited by 67
Zhang, R., Xu, S., Cai, Y., Zhou, M., Zuo, X., & Chan, P. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep075 · Cited by 64
BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease
Yong, J., Laćan, G., Dang, H. N., Hsieh, T., Middleton, B., Wasserfall, C. H., Tian, J., Melega, W. P., & Kaufman, D. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016610 · Cited by 64
Holasek, S. S., Wengenack, T. M., Kandimalla, K. K., Montaño, C., Gregor, D. M., Curran, G. L., & Poduslo, J. F. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.037 · Cited by 67
Carta, A. R., Kachroo, A., Schintu, N., Xu, K., Schwarzschild, M. A., Wardas, J., & Morelli, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06425.x · Cited by 64
Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat
Cho, I., Chung, Y. M., Park, C., Park, S.-H., Li, H. Y., Kim, D., Piao, Z. G., Choi, S., Lee, S. J., Park, K., et al. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.039 · Cited by 64
Carrasco, E., Casper, D., & Werner, P. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20541 · Cited by 64
Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller, K. M., Carty, M. L., Reinebrant, H. E., & Wixey, J. A. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21890 · Cited by 73
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
Bem, A. F. D., Krolow, R., Farias, H. R., de Rezende, V. L., Gelain, D. P., Moreira, J. C. F., Duarte, J. M. N., & de Oliveira, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604150 · Cited by 69
Pesticides, Microglial NOX2, and Parkinson's Disease
Taetzsch, T., & Block, M. L. (2013) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21464 · Cited by 62
Minocycline protects basal forebrain cholinergic neurons from mu p75‐saporin immunotoxic lesioning
Hunter, C. L., Quintero, E. M., Gilstrap, L., Bhat, N. R., & Granholm, A. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03439.x · Cited by 63
Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism
Hughes, E. H., Schlichtenbrede, F. C., Murphy, C. C., Broderick, C. A., van Rooijen, N., Ali, R. R., & Dick, A. D. (2004) · Experimental Eye Research · doi:10.1016/j.exer.2004.02.002 · Cited by 63
Lechpammer, M., Manning, S. M., Samonte, F., Nelligan, J., Sabo, E., Talos, D. M., Volpe, J. J., & Jensen, F. E. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00925.x · Cited by 63
Ahmed, A., Wang, L.-L., Abdel-Maksoud, S. A., Aboelgheit, A., Saeed, S., & Zhang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14450-5 · Cited by 66
Sugama, S., Wirz, S., Barr, A. M., Conti, B., Bartfai, T., & Shibasaki, T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.07.020 · Cited by 63
Microglia and Parkinson's disease: footprints to pathology
Lazdon, E., Stolero, N., & Frenkel, D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02154-6 · Cited by 61
Chandra, G., Roy, A., Rangasamy, S. B., & Pahan, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700149 · Cited by 62
Are rodent models of Parkinson’s disease behaving as they should?
Vingill, S., Connor‐Robson, N., & Wade‐Martins, R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.10.021 · Cited by 63
Litteljohn, D., Mangano, E. N., Shukla, N., & Hayley, S. P. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.09.025 · Cited by 61
Catalpol Exerts a Neuroprotective Effect in the MPTP Mouse Model of Parkinson’s Disease
Wang, L., Yu, X., Li, X., Zhao, Y., Wang, C., Wang, Z., & He, Z. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00316 · Cited by 61
Knyihár‐Csillik, E., Csillik, B., Pákáski, M., Krisztin‐Péva, B., Dobó, E., Okuno, E., & Vécsei, L. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.043 · Cited by 61
Rodriguez-Perez, A. I., Valenzuela, R., Villar‐Cheda, B., Guerra, M. J., & Labandeira-García, J. L. (2011) · Brain · doi:10.1093/brain/awr320 · Cited by 61
Watanabe, Y., Kato, H., & Araki, T. (2007) · Metabolic Brain Disease · doi:10.1007/s11011-007-9080-3 · Cited by 61
Neuroprotective Actions of Coenzyme Q10 in Parkinson's Disease
Sharma, S., Kheradpezhou, M., Shavali, S., Refaey, H. E., Eken, J., Hagen, C., & Ebadi, M. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82027-5 · Cited by 60
Kelly, R. L., Joers, V. L., Tansey, M. G., McKernan, D. P., & Dowd, E. (2020) · Molecules · doi:10.3390/molecules25030453 · Cited by 58
Duan, W., Gui, L., Zhou, Z., Liu, Y., Tian, H., Chen, J., & Zheng, J. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.05.010 · Cited by 60
Yan, K., Zhang, R., Sun, C., Chen, L., Li, P., Liu, Y., Peng, L., Sun, H., Qin, K., Chen, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084116 · Cited by 62
β1-integrin-dependent migration of microglia in response to neuron-released α-synuclein
Kim, C., Cho, E.-D., Kim, H.-K., You, S., Lee, H.-J., Hwang, D., & Lee, S. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.6 · Cited by 60
Tanrιöver, G., Seval, Y., Özsoy, Ö., Akkoyunlu, G., Savcıoğlu, F., Hacıoğlu, G., Demır, N., & Ağar, A. (2010) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0047-6 · Cited by 63
Manocha, G. D., Floden, A. M., Puig, K. L., Nagamoto‐Combs, K., Scherzer, C. R., & Combs, C. K. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0158-z · Cited by 60
Zhang, S., Goetz, B. D., & Duncan, I. D. (2002) · Glia · doi:10.1002/glia.10172 · Cited by 60
Immunotherapy for neurological diseases
Villoslada, P., Moreno, B., Melero, I., Pablos, J. L., Martino, G., Uccelli, A., Montalbán, X., Ávila, J., Rivest, S., Acarín, L., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.04.003 · Cited by 62
Heinisch, S., & Kirby, L. G. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.08.075 · Cited by 60
L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Serra, P. A., Impagnatiello, F., Morale, M. C., & Marchetti, B. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-83 · Cited by 59
Kumar, A., Chaudhary, T., & Mishra, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.057 · Cited by 59
Khasnavis, S., Ghosh, A., Roy, A., & Pahan, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.443556 · Cited by 59
Selective noradrenergic vulnerability in alpha-synuclein transgenic mice
Sotiriou, E., Vassilatis, D. K., Vila, M., & Stefanis, L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.010 · Cited by 59
Rodríguez‐Pallares, J., Parga, J. A., Joglar, B., Guerra, M. J., & Labandeira-García, J. L. (2011) · AGE · doi:10.1007/s11357-011-9284-7 · Cited by 57
The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders
Mediouni, S., Marcondes, M. C. G., Miller, C. A., McLaughlin, J. P., & Valente, S. T. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01164 · Cited by 61
Tripanichkul, W., & Eo, J. (2013) · PubMed · Cited by 59
Nicotinic Acetylcholine Receptor Signaling in Neuroprotection
Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 61
Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray
Mandel, S. A., Grünblatt, E., Maor, G., & Youdim, M. B. H. (2002) · Neurochemical Research · doi:10.1023/a:1020989812576 · Cited by 60
Minocycline Attenuates Cognitive Impairment Induced by Isoflurane Anesthesia in Aged Rats
Kong, F., Chen, S., Cheng, Y., Ma, L., Lu, H., Zhang, H., & Hu, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061385 · Cited by 58
Quintero, E. M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., & Granholm, A.-C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.104 · Cited by 58
Combined treatment with atorvastatin and minocycline suppresses severity of EAE
Luccarini, I., Ballerini, C., Biagioli, T., Biamonte, F., Bellucci, A., Rosi, M. C., Grossi, C., Massacesi, L., & Casamenti, F. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.01.022 · Cited by 58
Protection Against Parkinson’s Disease Progression: Clinical Experience
LeWitt, P. A., & Taylor, D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.007 · Cited by 57
Apolipoprotein E isoform‐dependent microglia migration
Cudaback, E., Li, X., Montine, K. S., Montine, T. J., & Keene, C. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-176891 · Cited by 58
Moreno, J. A., Streifel, K. M., Sullivan, K. A., Legare, M. E., & Tjalkens, R. B. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp221 · Cited by 57
Neuroinflammation and Parkinson's disease
Przedborski, S. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83026-0 · Cited by 60
Thomas, B., Banerjee, R., Starkova, N. N., Zhang, S. F., Calingasan, N. Y., Yang, L., Wille, E. J., Lorenzo, B. J., Ho, D. J., Beal, M. F., et al. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3849 · Cited by 58
Bridge Between Neuroimmunity and Traumatic Brain Injury
Kelso, M. L., & Gendelman, H. E. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113196660653 · Cited by 57
Huang, Q., Mao, X.-F., Wu, H., Li, T., Sun, M., Liu, H., & Wang, Y. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0696-2 · Cited by 57
Cheng, S., Hou, J., Zhang, C., Xu, C., Wang, L., Zou, X., Yu, H., Shi, Y. S., Yin, Z., & Chen, G. (2015) · Scientific Reports · doi:10.1038/srep10535 · Cited by 59
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 57
SHARMA, S. K., Refaey, H. E., & Ebadi, M. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.11.019 · Cited by 56
Ng, S. Y., Semple, B. D., Morganti-Kossmann, M. C., & Bye, N. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.2188 · Cited by 55
Minocycline Prevents Osmotic Demyelination Syndrome by Inhibiting the Activation of Microglia
Suzuki, H., Sugimura, Y., Iwama, S., Suzuki, H., Ozaki, N., Nagasaki, H., Arima, H., Sawada, M., & Oiso, Y. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040438 · Cited by 56
Ratai, E., Bombardier, J. P., Joo, C., Annamalai, L., Burdo, T. H., Campbell, J. H., Fell, R., Hakimelahi, R., He, J., Autissier, P., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010523 · Cited by 56
Minocycline and intracerebral hemorrhage: influence of injury severity and delay to treatment
Szymanska, A., Biernaskie, J. A., Laidley, D. T., Granter‐Button, S., & Corbett, D. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.09.011 · Cited by 56
Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity
McLaughlin, P., Zhou, Y., Ma, T., Liu, J., Zhang, W., Hong, J., Kovacs, M., & Zhang, J. (2006) · Glia · doi:10.1002/glia.20294 · Cited by 55
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
Hernandes, M. S., Santos, G. D. R., Café-Mendes, C. C., Lima, L. S., Scavone, C., Munhoz, C. D., & Britto, L. R. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075532 · Cited by 54
Bone marrow-derived mesenchymal stem cells modulate BV2 microglia responses to lipopolysaccharide
Ooi, Y. Y., Ramasamy, R., Rahmat, Z., Subramaiam, H., Tan, S. W., Abdullah, M., Israf, D. A., & Vidyadaran, S. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.09.001 · Cited by 55
Manganese-Induced NF-κB Activation and Nitrosative Stress Is Decreased by Estrogen in Juvenile Mice
Moreno, J. A., Streifel, K. M., Sullivan, K. A., Hanneman, W. H., & Tjalkens, R. B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr091 · Cited by 55
Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease
More, S. V., & Choi, D. (2017) · Nutrients · doi:10.3390/nu9050451 · Cited by 56
L ‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease
Tieu, K., Perier, C., Vila, M., Caspersen, C. S., Zhang, H., Teismann, P., Jackson-Lewis, V. R., Stern, D. M., Yan, S. D., & Przedborski, S. (2004) · Annals of Neurology · doi:10.1002/ana.20133 · Cited by 55
Clinical trials of neuroprotection for Parkinson’s disease
LeWitt, P. A. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s23 · Cited by 55
Peng, J., Xie, L., Stevenson, F. F., Melov, S., Di Monte, D. A., & Andersen, J. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3447-06.2006 · Cited by 53
Cai, Z., Yan, Y., Sun, S., Zhang, J., HUANG, L.-G., Yan, N., Wu, F., & Li, J. (2008) · Neuroscience Bulletin · doi:10.1007/s12264-008-0324-y · Cited by 56
Metadata
- Authors
- Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S.
- Affiliations
- Pediatrics and Genetics (US)
- Children's Hospital of Philadelphia (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 1763-1771
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6758858
- OpenAlex
- W2148726772
- Cited by
- 1,183
- References
- 44
- Citations by year
- 2026: 13 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 27 · 2021: 41 · 2020: 27 · 2019: 40 · 2018: 47 · 2017: 42 · 2016: 43 · 2015: 43 · 2014: 68 · 2013: 69 · 2012: 63
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Parkinson's Disease Foundation (NS38370)
- Muscular Dystrophy Association
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5r29ns037345-05, NS38370)
- National Institute on Aging (R01-AG13966, R01AG013966)
- National Institute of Neurological Disorders and Stroke (P50-NS38370, R01 NS 38586, R01 NS 42269, R29 NS37345, R01NS042269, R01NS038586, P50NS038370)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, minocycline, MPTP-induced neurotoxicity, neuroprotection, nitrotyrosine, IL-1β, NADPH oxidase, inducible nitric oxide synthase, nigrostriatal dopaminergic neurons, neuroinflammation, iNOS-deficient mice
- MeSH terms
- Animals, Anti-Bacterial Agents, Astrocytes, Corpus Striatum, Disease Models, Animal, Dose-Response Relationship, Drug, Interleukin-1, Mice, Inbred C57BL, Minocycline, Neurons, Substantia Nigra, Tyrosine, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Up-Regulation, Microglia, Mice, Knockout, Neuroprotective Agents, Nitric Oxide Synthase, NADPH Oxidases, Parkinsonian Disorders, Mice, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
